Gilead's experimental coronavirus drug, remdesivir, shows promise. The stock has been in news since the onset of the year on updates from the same.
South Korean contract drugs manufacturer Samsung Biologics Co Ltd said on Friday it had signed a deal worth more than $231 million with GlaxoSmithKline PLC (GSK) to supply biopharmaceutical products over the next eight years. The biotech arm of Samsung Group will start with manufacturing drugs for autoimmune disease lupus for GSK with the aim to expand to making other drugs for the British drugmaker, an official at Samsung Biologics told Reuters. "Samsung Biologics entered the biopharma industry with the goal to help our clients bring valuable biological medicines to patients faster," CEO Kim Tae-han said in a statement.
After taking over as chief executive of AstraZeneca in 2012, Pascal Soriot sent a team to a global life sciences conference to look for potential drug discovery partners. AstraZeneca’s repeated failure to find new drugs to replace one-time money-spinners as patents expired was not enticing. Seven years on, AstraZeneca has delivered one of the most striking turnrounds in global pharmaceuticals, producing a string of blockbuster cancer drugs that have catapulted it to the industry’s front ranks.
Biotech firm Novavax has entered its coronavirus vaccine in a Phase 1 clinical trial in Australia — the first in the Southern Hemisphere.
The coronavirus pandemic accelerated a wellness renaissance among consumers as shelter in place orders took effect, based on some of the sales trends seen by companies including Ro.
The Zacks Analyst Blog Highlights: Moderna, Pfizer, BioNTech, Sanofi and GlaxoSmithKline
GlaxoSmithKline has said it will produce 1bn doses of a vaccine booster as it steps up its preparations for an eventual immunisation for coronavirus. The London-listed pharmaceutical company, one of the world’s largest vaccine makers, said its adjuvant could make “a significant contribution against Covid-19”. “As demonstrated in the last flu pandemic, GSK’s pandemic adjuvant can reduce the amount of vaccine protein required per dose, which allows more vaccine doses to be produced, contributing to protecting more people,” GSK said.
GlaxoSmithKline (NYSE: GSK) is working with Mammoth Biosciences to develop a CRISPR-based test for SARS-CoV-2, the coronavirus that causes COVID-19. CRISPR is a gene-editing tool that's typically being used by companies and researchers aiming to develop cures for diseases. The system can edit DNA in a specific place by searching the DNA for a specific sequence, then cutting the DNA at that spot to make the edit.
Many biotech companies are coming up with impressive reports on their development of drugs, vaccines and therapies for COVID-19.
Here we highlight some ETFs for gaining exposure to the genomics market that is currently buzzing with opportunities for investors to cash on.
Cancer company has lost more than 90% of its market value in past five years Continue reading...
Vaccines are perceived as key to ending the restraints on work and life that have decimated the global economy, and returning to some sense of normalcy.
The world's largest vaccine maker said it was in talks with governments to back a manufacturing expansion that would help to scale up production of future vaccines for COVID-19, the disease caused by the novel coronavirus. It gave no indication of the programme's costs, saying only that production would take place at sites in Europe and North America and that it would reinvest any profit into coronavirus research and preparation for future pandemics. GSK is working on its own COVID vaccine with French drugmaker Sanofi
Vincent Chen wrote that it was “hard to pick winners” among the many Covid-19 vaccine programs, and that a vaccine wouldn’t be widely available until later next year.
Many countries are cautiously emerging from lockdown but life may not completely return to normal until a coronavirus vaccine is found.
Telehealth companies enabling individuals to see physicians without stepping foot into a physical doctor’s office are having their moment, as the coronavirus pandemic confines individuals and would-be patients across the country largely to their homes.
GlaxoSmithKline plc (LSE/NYSE: GSK) and Samsung Biologics (207940.KS) have entered into a partnership to provide GSK with additional capacity to manufacture and supply GSK's innovative biopharmaceutical therapies.
FDA approves line extensions for Bristol-Myers (BMY), Roche (RHHBY) and AstraZeneca (AZN)/Merck's (MRK) drugs. J&J stops sales of talc-based baby powders in the United States and Canada.
South Korean contract drugs manufacturer Samsung Biologics Co Ltd said on Friday it had signed a deal worth more than $231 million with GlaxoSmithKline PLC (GSK) to supply biopharmaceutical products over the next eight years. The biotech arm of Samsung Group will start with manufacturing drugs for autoimmune disease lupus for GSK with the aim to expand to making other drugs for the British drugmaker, an official at Samsung Biologics told Reuters. "Samsung Biologics entered the biopharma industry with the goal to help our clients bring valuable biological medicines to patients faster," CEO Kim Tae-han said in a statement.
Vanderbilt University School of Medicine,Professor of Medicine in the Division of Infectious Diseases Dr. William Schaffner joins Yahoo Finance’s Seana Smith to discuss the coronavirus, as a quarter of Americans say they are nervous about a vaccine, according to a new Reuters/Ipsos poll.